High-stability non-vesicle-type nano particle and application of same in therapy of helicobator pylori infection
A nanoparticle, non-vesicular technology, applied in the application of nanoparticles in the treatment of Helicobacter pylori infection, the field of highly stable, non-vesicular nanoparticles can solve the problem of affecting practical application value, producing drug-resistant strains, issues of limited stability
- Summary
- Abstract
- Description
- Claims
- Application Information
AI Technical Summary
Problems solved by technology
Method used
Image
Examples
preparation example Construction
[0102] Preparation method of non-vesicular nanoparticles of the present invention
[0103] The non-vesicular nanoparticles of the present invention can be prepared by the following method, comprising the following steps:
[0104] 1). Surfactants and optional lipids are suspended in water;
[0105] 2). Stir the suspension obtained in 1) until a homogeneous suspension is formed;
[0106] 3). Heating the homogeneous suspension obtained in 2) above the melting point of the surfactant and optional lipid it contains;
[0107] 4). Add the fatty acid to the hot suspension obtained in 3) and stir;
[0108] 5). Lower the temperature and let stand the suspension obtained in 4), so as to obtain the non-vesicular nanoparticle suspension of the present invention.
[0109] In a specific embodiment, the melting temperature in the method is 20-80°C, such as 20°C, 30°C, 40°C, 50°C, 60°C, 70°C or 80°C.
[0110] In further embodiments, the method may further comprise measuring the hydrodynami...
Embodiment 1
[0149] Embodiment 1 Preparation and characterization of nanoparticles of the present invention
[0150] Nanoparticles of the invention were prepared as described in the "Materials and Methods" section.
[0151] The present inventors prepared nanoparticles of the present invention with different myristoleic acid loadings ranging from 0.1-4% w / v, such as figure 1As shown, an optimal yield of nanoparticles was thus selected while maintaining an acceptable nanoparticle size (approximately 9 nm). The inventors found that when the initial loading concentration of myristoleic acid increased, the nanoparticle size also increased ( figure 2 ). The best formulation chosen for subsequent experiments was 0.3% w / v myristoleic acid (2:1 mass ratio lipid to surfactant) with an average particle size of approximately 8.6 nm, below the threshold of 10 nm. The quality of the nanoparticles was detected by dynamic light scattering and characterized by the polydispersity parameter. The PDI of ...
Embodiment 2
[0153] Example 2. In vitro antibacterial activity of nanoparticles of the present invention
[0154] The effect of the nanoparticles of the present invention on Helicobacter pylori (Sydney strain 1, HPSS1) was determined by the MIC (defined as the lowest concentration that inhibits bacterial growth) and MBC (defined as the lowest that kills 99.9% of target bacteria) values against Helicobacter pylori. In vitro antibacterial activity.
[0155] For determination of MIC, 0.05OD 600 (corresponding to 5×10 6 CFU / mL) of Helicobacter pylori were co-cultured with different concentrations (0 to 0.012% w / v) of the nanoparticles of the present invention. To quantify bacterial growth, after 18 hours of incubation, determine the OD of the bacterial culture 600 value, records the change value compared to the initial value. The change value reflects the growth of bacteria under the influence of the nanoparticles of the invention. Such as Figure 5 As shown, when the concentration of ...
PUM
| Property | Measurement | Unit |
|---|---|---|
| particle diameter | aaaaa | aaaaa |
| particle diameter | aaaaa | aaaaa |
| particle diameter | aaaaa | aaaaa |
Abstract
Description
Claims
Application Information
Login to View More